Related Experiment Video

Updated: Aug 29, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Fungal infections in neutropenic cancer patients

Tariq Parvez1

  • 1Department of Oncology, King Fahad Hospital, Al-Madina Al-Munawra, Kingdom of Saudi Arabia. tariq_parvez52@hotmail.com

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|January 1, 2004
PubMed

Insights

Cancer patients with neutropenia face life-threatening invasive fungal infections. Emerging fungal pathogens show resistance to antifungals, necessitating novel prevention and treatment strategies.

Area of Science:

  • Oncology
  • Mycology
  • Infectious Diseases

Background:

  • Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality in cancer patients experiencing prolonged neutropenia post-chemotherapy.
  • Current trends show an increase in infections caused by resistant Aspergillus species, non-albicans Candida species, and rare fungal pathogens.
  • These emerging pathogens exhibit reduced susceptibility to existing antifungal therapies.

Purpose of the Study:

  • To review current strategies for preventing and treating opportunistic fungal infections in neutropenic cancer patients.
  • To discuss emerging antifungal approaches and supportive care methods to address changing trends in IFIs.

Main Methods:

  • Literature review of recent studies on antifungal prophylaxis and treatment in neutropenic cancer patients.
  • Analysis of trends in fungal pathogen prevalence and antifungal susceptibility.
  • Discussion of novel therapeutic agents and supportive care interventions.

Main Results:

  • Identification of a shift towards infections by drug-resistant fungal species, including Aspergillus and non-albicans Candida.
  • Highlighting the decreased efficacy of standard antifungal agents against these emerging pathogens.
  • Review of various prophylactic and therapeutic regimens, noting their limitations.

Conclusions:

  • There is an urgent need for new antifungal agents and treatment strategies to combat resistant fungal infections in immunocompromised cancer patients.
  • Optimizing supportive care alongside novel antifungal approaches is crucial for improving outcomes.
  • Continued research into emerging fungal pathogens and their susceptibility patterns is essential.

More Related Videos

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...